April 25th 2024
Findings from the CARTITUDE-2 trial support the use of cilta-cel in patients with multiple myeloma, says Tina Glow, AAS, RN, BSN.
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Management of Bispecific Toxicities and Final Thoughts on Treatments in MM
Closing out the panel discussion, experts review the management of bispecific-related toxicities and share their final thoughts on treating patients with multiple myeloma.
The Role of Belantamab Mafodotin and Its Impact on Future Treatment Options
Expert oncologists discuss Belantamab mafodotin, its recent withdrawal from the U.S. market, and the clinical implications of the DREAMM trials for patients with R/R multiple myeloma.
Ongoing Trials Aim to Determine Best Regimen for Transplant-Ineligible Patients With Myeloma
March 1st 2023Luciano J. Costa, MD, PhD, discussed additional studies evaluating various treatment regimens for transplant-ineligible patients with newly diagnosed multiple myeloma, aiming to determine the best standard in this population.
GRIFFIN Trial Supports Use of Dara-VRd in Transplant-Eligble Patients With Myeloma
February 28th 2023Luciano J. Costa, MD, PhD, discussed the results from the phase 2 GRIFFIN study, designed to evaluate the combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in transplant-eligible patients with multiple myeloma.
Rationale for Bispecific-Based Combinations in MM
Shared perspective on the potential role of ADCs, CAR T-cell therapy, and other agents in combination treatment with bispecifics for patients with multiple myeloma.
Treatment Selection of Bispecifics in Relapsed-Refractory MM
Focusing their discussion on clinical data in R/R multiple myeloma studies, panelists highlight current and emerging bispecific antibodies for treating patients that have progressed after multiple lines of therapy.
MAIA trial Supports Use of D-Rd in Transplant-Ineligible Patients With Myeloma
February 27th 2023Luciano J. Costa, MD, PhD discussed updating findings from the phase 3 MAIA trial of the triplet combination of daratumumab, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma.
Unmet Needs and Future Directions in Care in Multiple Myeloma
Closing out their discussion on the management of multiple myeloma, expert panelists highlight unmet needs and look toward future directions in care.
ctDNA May Replace Bone Marrow Exams in Multiple Myeloma, Expert Says
February 23rd 2023An expert from Stanford Medicine that the goal behind a study characterizing circulating tumor DNA and its predictive value is to eventually replace blood marrow exams with a blood draw for those with multiple myeloma.
Panobinostat Regimen Yields Benefit for R/R Myeloma After Frontline ASCT
February 23rd 2023Evidence from a matched pair comparison with a concurrent control cohort suggests that panobinostat plus gemcitabine, busulfan, and melphalan improves progression-free survival in those with relapsed or refractory multiple myeloma, especially after first transplant.
Discussing Consent for Supportive Care Agents with Patients with Multiple Myeloma
February 22nd 2023Nurse Practitioner Kiah Purcell explains how she discusses supportive care agents with patients receiving a BCMA-targeting bispecific for multiple myeloma in case a patient experiences cytokine release syndrome.
Treatment Approaches for Patients with Relapsed-Refractory MM
Expert panelists discuss treatment approaches for patient with multiple myeloma that have progressed and are relapsed and/or refractory (R/R).
What is the Role of CAR T-Cell Therapy in R/R MM?
Expert perspectives on the advent of CAR T-cell therapy in relapsed/refractory multiple myeloma, and how its role may integrate with bispecific antibody therapy.
R/R MM: Optimizing Treatment Sequencing With Bispecific Antibodies
Before closing out their discussion on bispecific antibodies in relapsed/refractory multiple myeloma, key opinion leaders consider optimal sequencing of these agents.